SAN ANTONIO, Sept. 16, 2011 /PRNewswire/ -- Aperion Biologics, Inc. announced today that the company will be presenting at the 2011 UBS Global Life Sciences Conference at the Grand Hyatt New York on Wednesday, September 21, 2011 at 3:00 PM (EDT).
Daniel Lee, Chief Executive Officer, is scheduled to present an overview of the Company's unique technology, clinical progress and plans for commercialization.
Interested parties may listen to the live webcast and view a copy of the slide presentations by visiting the "News/Events" section of the Company's web site at www.aperionbiologics.com.
About Aperion Biologics, Inc.
Aperion Biologics, Inc., located in San Antonio, Texas, is a privately owned, clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology. Aperion developed and patented a technique to make animal tissues compatible for challenging human applications. The core platform technology utilizes the Company's proprietary Z-Process, which removes the key carbohydrate antigens from animal tissues followed by a unique conversion process that both stabilizes and sterilizes the tissue without affecting its biomechanical or biological properties. This creates functioning scaffolds capable of remodeling into healthy tissue. Aperion's Z-Process is applicable to a variety of tissues used in orthopaedic, cardiovascular, plastic, dermatologic, general and other surgical specialties. The company's lead product for ligament reconstruction procedures, the Z-Lig ACLR Device, is currently in clinical investigation and not commercially approved for sale in the United States or other markets.
SOURCE Aperion Biologics, Inc.